Research Context
Our TB-500 vial — known across community terminology simply as "TB" — is a synthetic fragment of Thymosin Beta-4, supplied at >99% HPLC purity for actin-regulation and tissue-migration research.
TB is a staple research compound in regeneration protocols and a co-ingredient in the WOLVERINE STACK, GLOW STACK, and KLOW STACK. These compounds are studied for vascular development and cellular migration pathways.
A synthetic fragment of Thymosin Beta-4 researched for its role in actin regulation and cellular migration.
99% HPLC Purity · For Laboratory Research Use Only
Key Research Findings (At a Glance)
| Parameter | Summary |
|---|---|
| Peptide Structure | 43 amino acids (synthetic human Thymosin Beta-4 sequence) |
| Origin | Endogenous protein found in nearly all human and animal cells |
| Primary Mechanism | G-actin sequestration, cell migration, anti-fibrotic signaling |
| Key Research Areas | Muscle/tendon repair, wound healing, cardiac tissue recovery, anti-scarring |
| Distinguishing Feature | Promotes healing while actively reducing scar tissue and fibrosis |
| Key Differentiator from BPC-157 | Targets cellular migration and actin dynamics; BPC-157 targets angiogenesis |
| Common Dosage Range (Preclinical) | 200–500 mcg per administration (subcutaneous) |
| Typical Administration | Subcutaneous injection (systemic) |
| Intended Use | Laboratory research only – not for human or veterinary consumption |
Overview
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino-acid protein found in nearly all human and animal tissues. Frequently referenced in research communities simply as TB-500 or TB4, this peptide is heavily investigated for its profound ability to promote tissue regeneration, accelerate wound healing, and reduce inflammation.
Investigators who buy research-grade TB-500 select it because, unlike many growth factors that only stimulate tissue growth, TB-500 uniquely orchestrates the entire healing process, from initial cell migration to final tissue remodeling. It is frequently compared with BPC-157 in connective-tissue research protocols.
The primary mechanism of TB-500 involves the sequestration of G-actin (globular actin), preventing it from polymerizing into F-actin (filamentous actin). This regulation of the actin cytoskeleton is the fundamental driver of cell motility, directing keratinocytes, endothelial cells, and fibroblasts to migrate efficiently to sites of injury and facilitating rapid tissue repair.
TB-500 is also highly valued for its systemic efficacy and anti-fibrotic properties. Research consistently demonstrates that it accelerates the healing of muscle, tendon, and cardiac tissue while actively downregulating transforming growth factor-beta 1 (TGF-β1), a primary driver of excessive scar tissue formation.
Researchers looking for TB-500 for sale typically pair it with GHK-Cu when investigating dermal regeneration alongside soft-tissue repair, making TB-500 a critical compound for studying functional tissue regeneration rather than simple scar-based repair.
Mechanism of Action: Actin Regulation and Anti-Fibrotic Signaling
G-Actin Sequestration and Cell Migration
The core function of TB-500 is binding to and sequestering monomeric G-actin. By maintaining a pool of available G-actin, TB-500 allows cells to rapidly assemble and disassemble their cytoskeletons. This dynamic remodeling is essential for cell motility, enabling repair cells to migrate quickly and efficiently to the site of tissue damage, which is the critical first step in the healing cascade.
Angiogenesis and Wound Healing
TB-500 upregulates the expression of vascular endothelial growth factor (VEGF) and promotes the migration of endothelial cells. This stimulates the formation of new blood vessels (angiogenesis) at the injury site, ensuring that the newly forming tissue receives adequate oxygen and nutrients. Research shows this significantly accelerates wound closure rates and improves the quality of granulation tissue.
Anti-Fibrotic and Anti-Inflammatory Effects
A major complication in tissue repair is the formation of dense, non-functional scar tissue (fibrosis). TB-500 actively modulates the inflammatory response by downregulating pro-inflammatory cytokines and inhibiting TGF-β1 signaling. This reduces excessive collagen deposition and scar tissue formation, promoting the regeneration of functional, flexible tissue that closely resembles the original, uninjured state.
Why Researchers Choose TB-500 Over Other Recovery Peptides
Versus BPC-157: While both are premier recovery peptides, they target different phases of healing. BPC-157 primarily drives angiogenesis and gut mucosal healing. TB-500 primarily regulates cell migration and prevents fibrosis. Researchers choose TB-500 when the goal is to minimize scar tissue and promote functional soft tissue regeneration, whereas BPC-157 is selected for vascularization and connective tissue repair.
Versus GHK-Cu: GHK-Cu is a copper-binding tripeptide that primarily stimulates collagen synthesis and extracellular matrix (ECM) remodeling, making it ideal for dermal and skin research. TB-500 has a broader systemic effect on muscle, tendon, cardiac, and neural tissues, making it the preferred choice for deep tissue and structural injury models.
Versus Traditional Growth Factors: Many traditional growth factors (like PDGF or FGF) can promote healing but often at the cost of excessive fibrosis or uncontrolled cell proliferation. TB-500 provides a more balanced, physiological approach to healing by promoting regeneration while actively suppressing pathological scar formation.
Primary Research Applications
- Skeletal muscle tear and strain regeneration models
- Tendon and ligament injury repair (often combined with BPC-157)
- Anti-fibrotic and scar tissue reduction studies
- Corneal wound healing and ocular surface regeneration studies
- Cardiac tissue recovery post-myocardial infarction
- Peripheral nerve injury and neuroregeneration research
- Hair follicle regeneration and dermal remodeling studies
- Comparative tissue repair studies (vs. BPC-157, GHK-Cu)
TB-500 vs. BPC-157 vs. GHK-Cu: Comparative Recovery and Healing Analysis
Researchers frequently compare these three peptides to understand distinct pathways through which they promote tissue repair, regeneration, and recovery.
| Feature | TB-500 | BPC-157 | GHK-Cu |
|---|---|---|---|
| Peptide Length | 43 amino acids | 15 amino acids | 3 amino acids |
| Origin | Thymosin Beta-4 (endogenous) | Human gastric juice protein | Endogenous human plasma/urine/saliva |
| Primary Mechanism | G-actin sequestration, cell migration, anti-fibrotic | VEGF upregulation, NO modulation, angiogenesis | Collagen synthesis, ECM remodeling, copper delivery |
| Primary Research Focus | Soft tissue regeneration, cell migration, wound healing | Tendon/ligament repair, gut healing, angiogenesis | Dermal regeneration, skin remodeling, anti-aging |
| Key Tissue Target | Muscle, skin, cardiac tissue, CNS | Connective tissue, gut mucosa, vasculature | Skin, dermis, hair follicles, connective tissue |
| Physiological Profile | Pro-migratory, anti-fibrotic, anti-inflammatory | Angiogenic, cytoprotective, gastroprotective | Remodeling, collagen-stimulating, antioxidant |
| Typical Research Dosing Scale | Micrograms (mcg) | Micrograms (mcg) | Micrograms to milligrams (mcg-mg) |
Note: While all three peptides promote tissue repair, TB-500 is distinguished by its cell-migratory and anti-fibrotic profile, making it the primary choice for soft tissue regeneration and scar reduction. BPC-157 is preferred for angiogenesis and gut research, while GHK-Cu is selected for dermal and collagen remodeling. Formulation ratios and purity metrics may vary by batch.
Product Specifications
Chemical Specifications
| Specification | Value |
|---|---|
| Peptide Sequence | 43 Amino Acids (Human Thymosin Beta-4 Sequence) |
| CAS Number | 77095-66-2 |
| Synonyms | TB-500, Thymosin Beta-4, TB4 |
| Molecular Formula | C₂₁₂H₃₅₀N₅₆O₇₈S |
| Molar Mass | ~4963.5 g/mol |
| Peptide Length | 43 amino acids |
| Purity | ≥99% by HPLC |
| Form | Lyophilized white powder |
Note: Formulation ratios and purity metrics may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition and laboratory-verified specifications.
Storage and Stability
| Condition | Recommendation |
|---|---|
| Long-term storage (lyophilized) | −20°C in tightly sealed container, protected from light and moisture – stable for up to 24 months |
| Shipping | Room temperature (15–25°C) for short periods (up to two weeks) – no significant degradation |
| After reconstitution | Refrigerate at 2–8°C; use within 28 days |
| Handling precautions | Avoid repeated freeze-thaw cycles and vigorous shaking to maintain peptide integrity |
Research Protocol Considerations
TB-500 is typically reconstituted with bacteriostatic water. In preclinical research models, TB-500 is evaluated in microgram (mcg) quantities, with common protocols ranging from 200–500 mcg per administration. Researchers typically use reconstitution volumes of 1–3 mL to allow for precise measurement with standard insulin syringes. Administration is most frequently via subcutaneous injection, as TB-500 exhibits strong systemic efficacy, traveling through the bloodstream to reach distant injury sites.
Investigators studying comprehensive recovery protocols often research TB-500 alongside other tissue repair peptides. A highly common research design involves combining TB-500 (for cell migration and anti-fibrotic effects) with BPC-157 (for angiogenesis and connective tissue repair), as their complementary mechanisms are frequently studied for synergistic healing outcomes.
Research Dosing Considerations
In preclinical research models, TB-500 is evaluated in microgram (mcg) quantities, with common protocols ranging from 200–500 mcg per administration. Administration is most frequently via subcutaneous injection, as TB-500 exhibits strong systemic efficacy. Researchers typically use reconstitution volumes of 1–3 mL for precise measurement.
TB-500 Research FAQ
Q: Is TB-500 approved for human use in research quantities?
A: Research-grade TB-500 is currently available for preclinical research only. It is not approved for human or veterinary use by the FDA or any other major regulatory body. It is supplied as a lyophilized powder for laboratory research purposes only. Researchers should consult all applicable institutional and regulatory guidelines before initiating study protocols.
Q: What is the primary mechanism of TB-500 in tissue regeneration research?
A: TB-500 (Thymosin Beta-4 fragment) primarily regulates the actin cytoskeleton by sequestering G-actin (globular actin), preventing it from polymerizing into F-actin. This regulation of actin dynamics directs keratinocytes, endothelial cells, and fibroblasts to migrate efficiently to sites of injury, facilitating rapid tissue repair.
Q: Does TB-500 cause scar tissue or fibrosis?
A: No, quite the opposite. One of the most valuable properties of TB-500 is its anti-fibrotic effect. Research demonstrates that TB-500 downregulates TGF-β1, a primary driver of excessive collagen deposition. By inhibiting this pathway, TB-500 actively reduces scar tissue formation, promoting regeneration of flexible, functional tissue rather than rigid scar tissue.
Q: What is the difference between TB-500 and BPC-157?
A: TB-500 is a 43-amino-acid Thymosin Beta-4 fragment that regulates actin dynamics, promoting cell migration and reducing fibrosis. BPC-157 is a 15-amino-acid gastric-derived peptide that primarily drives angiogenesis via VEGF upregulation. TB-500 is preferred for soft tissue regeneration and anti-scarring studies, while BPC-157 is selected for vascularization and connective tissue repair.
Q: What is the difference between TB-500 and the Ac-SDKP fragment?
A: TB-500 refers to the synthetic version of the full 43-amino-acid sequence of human Thymosin Beta-4. Ac-SDKP is a much smaller, 4-amino-acid fragment located at the N-terminus. While both are derived from the same parent protein, TB-500 contains the full sequence required for comprehensive actin regulation and broad tissue regeneration.
Q: Can TB-500 be stacked with BPC-157 in research protocols?
A: Yes, researchers frequently combine TB-500 and BPC-157 in preclinical models to study synergistic tissue repair effects. TB-500 promotes cell migration and reduces fibrosis, while BPC-157 improves blood supply via angiogenesis. Researchers typically reconstitute each peptide separately and administer them as distinct interventions.
Scientific References and Citations
- Goldstein AL, Hannapel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.003
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 and its fragment KTTKS stimulate matrix metalloproteinase expression in human dermal fibroblasts. Ann N Y Acad Sci. 1999;885:422-424. doi:10.1111/j.1749-6632.1999.tb09785.x
- Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2007;84(2):297-304. doi:10.1016/j.exer.2006.09.016
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
- Philp D, Scheremeta B, Sibliss K, et al. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol. 2006;208(1):195-200. doi:10.1002/jcp.20646
- Hocking DC, Sottile J, Langenbach KJ. Stimulation of actin polymerization by a short peptide derived from the actin-binding domain of thymosin beta-4. J Biol Chem. 2001;276(3):1864-1869. doi:10.1074/jbc.M008287200
